Predictive value of the Age-Adjusted Charlson Comorbidity Index on perioperative complications and survival in patients undergoing primary debulking surgery for advanced epithelial ovarian cancer

Gynecologic Oncology

Volumn 138, Issue 2, 2015, Pages 246-251

  Suidan, Rudy S ^a   Leitao, Mario M ^a,b   Zivanovic, Oliver ^a,b   Gardner, Ginger J ^a,b   Long Roche, Kara C ^a   Sonoda, Yukio ^a,b   Levine, Douglas A ^a,b   Jewell, Elizabeth L ^a,b   Brown, Carol L ^a,b   Abu Rustum, Nadeem R ^a,b   Charlson, Mary E ^b   Chi, Dennis S ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Age Adjusted Charlson Comorbidity Index; Ovarian cancer; Overall survival; Perioperative complications; Progression free survival

Indexed keywords

ADULT; AGE ADJUSTED CHARLSON COMORBIDITY INDEX; AGED; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CHARLSON COMORBIDITY INDEX; CHRONIC LUNG DISEASE; CONFERENCE PAPER; CONNECTIVE TISSUE DISEASE; CYTOREDUCTIVE SURGERY; DIABETES MELLITUS; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; LUNG COMPLICATION; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; OVARY CARCINOMA; OVERALL SURVIVAL; PEROPERATIVE COMPLICATION; POSTOPERATIVE INFECTION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; WOUND COMPLICATION; ADVERSE EFFECTS; AGE; DISEASE FREE SURVIVAL; FALLOPIAN TUBE NEOPLASMS; GYNECOLOGIC SURGERY; MIDDLE AGED; MORBIDITY; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PATHOLOGY; PERIOPERATIVE PERIOD; PERITONEAL NEOPLASMS; POSTOPERATIVE COMPLICATIONS; PROCEDURES; RETROSPECTIVE STUDY; SURVIVAL RATE; YOUNG ADULT;

ADULT; AGE FACTORS; DISEASE-FREE SURVIVAL; FALLOPIAN TUBE NEOPLASMS; FEMALE; GYNECOLOGIC SURGICAL PROCEDURES; HUMANS; MIDDLE AGED; MORBIDITY; NEOPLASM STAGING; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PERIOPERATIVE PERIOD; PERITONEAL NEOPLASMS; POSTOPERATIVE COMPLICATIONS; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; SURVIVAL RATE; YOUNG ADULT;

EID: 84938214952     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2015.05.034     Document Type: Conference Paper

References (35)

1. R.L. Siegel, K.D. Miller, and A. Jemal Cancer statistics, 2015 CA Cancer J. Clin. 65 2015 5 29
2. R.F. Ozols, B.N. Bundy, B.E. Greer, J.M. Fowler, D. Clarke-Pearson, R.A. Burger, and et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study J. Clin. Oncol. 21 2003 3194 3200
3. W.E. Winter, G.L. Maxwell, C. Tian, J.W. Carlson, R.F. Ozols, P.G. Rose, and et al. Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study J. Clin. Oncol. 25 2007 3621 3627
4. S.J. Chang, M. Hodeib, J. Chang, and R.E. Bristow Survival impact of complete cytoreduction to no gross residual disease for advanced-stage ovarian cancer: a meta-analysis Gynecol. Oncol. 130 2013 493 498
5. D.S. Chi, C.C. Franklin, D.A. Levine, F. Akselrod, P. Sabbatini, W.R. Jarnagin, and et al. Improved optimal cytoreduction rates for stages IIIC and IV epithelial ovarian, fallopian tube, and primary peritoneal cancer: a change in surgical approach Gynecol. Oncol. 94 2004 650 654
6. D.S. Chi, O. Zivanovic, K.L. Levinson, V. Kolev, J. Huh, J. Dottino, and et al. The incidence of major complications after the performance of extensive upper abdominal surgical procedures during primary cytoreduction of advanced ovarian, tubal, and peritoneal carcinomas Gynecol. Oncol. 119 2010 38 42
7. S.C. Dowdy, R.T. Loewen, G. Aletti, S.S. Feitoza, and W. Cliby Assessment of outcomes and morbidity following diaphragmatic peritonectomy for women with ovarian carcinoma Gynecol. Oncol. 109 2008 303 307
8. E.L. Eisenhauer, M.I. D'Angelica, N.R. Abu-Rustum, Y. Sonoda, W.R. Jarnagin, R.R. Barakat, and et al. Incidence and management of pleural effusions after diaphragm peritonectomy or resection for advanced mullerian cancer Gynecol. Oncol. 103 2006 871 877
9. P.M. Magtibay, P.B. Adams, M.B. Silverman, S.S. Cha, and K.C. Podratz Splenectomy as part of cytoreductive surgery in ovarian cancer Gynecol. Oncol. 102 2006 369 374
10. S.M. Eisenkop, N.M. Spirtos, and W.C. Lin Splenectomy in the context of primary cytoreductive operations for advanced epithelial ovarian cancer Gynecol. Oncol. 100 2006 344 348
11. S.M. Kehoe, E.L. Eisenhauer, N.R. Abu-Rustum, Y. Sonoda, M. D'Angelica, W.R. Jarnagin, and et al. Incidence and management of pancreatic leaks after splenectomy with distal pancreatectomy performed during primary cytoreductive surgery for advanced ovarian, peritoneal and fallopian tube cancer Gynecol. Oncol. 112 2009 496 500
12. J.O. Schorge, R.M. Clark, S.I. Lee, and R.T. Penson Primary debulking surgery for advanced ovarian cancer: are you a believer or a dissenter? Gynecol. Oncol. 135 2014 595 605
13. T.L. Jorgensen, S. Teiblum, M. Paludan, L.O. Poulsen, A.Y. Jorgensen, K.H. Bruun, and et al. Significance of age and comorbidity on treatment modality, treatment adherence, and prognosis in elderly ovarian cancer patients Gynecol. Oncol. 127 2012 367 374
14. C. Langstraat, G.D. Aletti, and W.A. Cliby Morbidity, mortality and overall survival in elderly women undergoing primary surgical debulking for ovarian cancer: a delicate balance requiring individualization Gynecol. Oncol. 123 2011 187 191
15. J.D. Wright, C.V. Ananth, J. Tsui, S.A. Glied, W.M. Burke, Y.S. Lu, and et al. Comparative effectiveness of upfront treatment strategies in elderly women with ovarian cancer Cancer 120 2014 1246 1254
16. M.E. Charlson, P. Pompei, K.L. Ales, and C.R. MacKenzie A new method of classifying prognostic comorbidity in longitudinal studies: development and validation J. Chronic Dis. 40 1987 373 383
17. K.D. Aaronson, J.S. Schwartz, T.M. Chen, K.L. Wong, J.E. Goin, and D.M. Mancini Development and prospective validation of a clinical index to predict survival in ambulatory patients referred for cardiac transplant evaluation Circulation 95 1997 2660 2667
18. J.F. Piccirillo Importance of comorbidity in head and neck cancer Laryngoscope 110 2000 593 602
19. D.S. Lee, P.C. Austin, J.L. Rouleau, P.P. Liu, D. Naimark, and J.V. Tu Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model JAMA 290 2003 2581 2587
20. M. Charlson, T.P. Szatrowski, J. Peterson, and J. Gold Validation of a combined comorbidity index J. Clin. Epidemiol. 47 1994 1245 1251
21. J.D. Wright, S.N. Lewin, I. Deutsch, W.M. Burke, X. Sun, A.I. Neugut, and et al. Defining the limits of radical cytoreductive surgery for ovarian cancer Gynecol. Oncol. 123 2011 467 473
22. G.D. Aletti, S.C. Dowdy, K.C. Podratz, and W.A. Cliby Relationship among surgical complexity, short-term morbidity, and overall survival in primary surgery for advanced ovarian cancer Am. J. Obstet. Gynecol. 197 2007 1 7
23. J.N. Barlin, C. Yu, E.K. Hill, O. Zivanovic, V. Kolev, D.A. Levine, and et al. Nomogram for predicting 5-year disease-specific mortality after primary surgery for epithelial ovarian cancer Gynecol. Oncol. 125 2012 25 30
24. R.M. Clark, M.S. Lee, J. Alejandro Rauh-Hain, T. Hall, D.M. Boruta, M.G. Del Carmen, and et al. Surgical Apgar Score and prediction of morbidity in women undergoing hysterectomy for malignancy Gynecol. Oncol. 136 2015 516 520
25. M.S. Tetsche, C. Dethlefsen, L. Pedersen, H.T. Sorensen, and M. Norgaard The impact of comorbidity and stage on ovarian cancer mortality: a nationwide Danish cohort study BMC Cancer 8 2008 31
26. C. Sperling, M.C. Noer, I.J. Christensen, M.L.S. Nielsen, O. Lidegaard, and C. Høgdall Comorbidity is an independent prognostic factor for the survival of ovarian cancer: a Danish register-based cohort study from a clinical database Gynecol. Oncol. 129 2013 97 102
27. R.C. Martin II, D.P. Jaques, M.F. Brennan, and M. Karpeh Achieving R0 resection for locally advanced gastric cancer: is it worth the risk of multiorgan resection? J. Am. Coll. Surg. 194 2002 568 577
28. S.R. Grobmyer, F.M. Pieracci, P.J. Allen, M.F. Brennan, and D.P. Jaques Defining morbidity after pancreaticoduodenectomy: use of a prospective complication grading system J. Am. Coll. Surg. 204 2007 356 364
29. G.D. Aletti, S.C. Dowdy, B.S. Gostout, M.B. Jones, R.C. Stanhope, T.O. Wilson, and et al. Quality improvement in the surgical approach to advanced ovarian cancer: the Mayo Clinic experience J. Am. Coll. Surg. 208 2009 614 620
30. P. Therasse, S.G. Arbuck, E.A. Eisenhauer, J. Wanders, R.S. Kaplan, L. Rubinstein, and et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J. Natl. Cancer Inst. 92 2000 205 216
31. G.J. Rustin, M. Marples, A.E. Nelstrop, M. Mahmoudi, and T. Meyer Use of CA-125 to define progression of ovarian cancer in patients with persistently elevated levels J. Clin. Oncol. 19 2001 4054 4057
32. M. Markman, J.L. Lewis, P. Saigo, T. Hakes, S. Rubin, W. Jones, and et al. Impact of age on survival of patients with ovarian cancer Gynecol. Oncol. 49 1993 236 239
33. K.S. Matthews, K.E. Hoskins, M.K. Kemper, W. Wang, J.M. Straughn, and R.P. Rocconi The impact of age on the treatment and survival of ovarian cancer patients Clin. Ovarian Cancer 3 2010 122 125
34. S.M.H. Alibhai, M. Leach, G. Tomlinson, M.D. Krahn, N. Fleshner, E. Holowaty, and et al. 30-Day mortality and major complications after radical prostatectomy: influence of age and comorbidity J. Natl. Cancer Inst. 97 2005 1525 1532
35. S. Houterman, M.L.G. Janssen-Heijnen, C.D.G.W. Verheij, W.J. Louwman, G. Vreugdenhil, M.J.C. van der Sangen, and et al. Comorbidity has negligible impact on treatment and complications but influences survival in breast cancer patients Br. J. Cancer 90 2004 2332 2337